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Estimating Missing Heritability for Disease
from Genome-wide Association Studies
Sang Hong Lee,1 Naomi R. Wray,1 Michael E. Goddard,2,3 and Peter M. Visscher1,*
Genome-wide association studies are designed to discover SNPs that are associated with a complex trait. Employing strict significance
thresholds when testing individual SNPs avoids false positives at the expense of increasing false negatives. Recently, we developed
a method for quantitative traits that estimates the variation accounted for when fitting all SNPs simultaneously. Here we develop
this method further for case-control studies. We use a linear mixed model for analysis of binary traits and transform the estimates to
a liability scale by adjusting both for scale and for ascertainment of the case samples.We show by theory and simulation that themethod
is unbiased. We apply the method to data from the Wellcome Trust Case Control Consortium and show that a substantial proportion of
variation in liability for Crohn disease, bipolar disorder, and type I diabetes is tagged by common SNPs.Introduction
Heritability is a general and key population parameter that
can help understand the genetic architecture of complex
traits. It is usually defined as the proportion of total pheno-
typic variation that is due to additive genetic factors.1
Methods of obtaining unbiased estimates of heritability
from pedigree data are well established for continuous
phenotypes, for example (restricted) maximum likelihood
for linear mixed models (LMM).2–5 For binary traits, such
as disease, familial resemblance is usually parameterized
on an unobserved continuous liability scale so that the
heritability is independent of disease prevalence.6 With
genome-wide genotype data, we can derive estimates of
genetic variance tagged by the SNPs from samples of indi-
viduals who are unrelated in the conventional sense.7 Heri-
tability estimated from pedigree data is not the same as the
proportion of phenotypic variation explained by all SNPs
because the former includes the contribution of all causal
variants, whereas the latter only includes the contribution
of causal variants that are in linkage disequilibrium (LD)
with the genotyped SNPs.8
Genome-wide association studies (GWAS) have reported
hundreds of SNPs that are robustly associated with one or
more complex traits, including quantitative traits and
common disease.9 Typically, the associated SNPs in total
only explain a small proportion of the genetic variation
in the population, and this observation has led to the
perceived problem of ‘‘missing heritability.’’10,11 We have
argued previously that the two most plausible explana-
tions for these observations are that either the effect sizes
at individual SNPs are so small that they do not reach
genome-wide significance in GWAS or that causal variants
are not in sufficient LD with SNPs on the commercial
arrays to be detected by association.7,12 For example, insuf-
ficient LD could arise if causal variants have lower minor
allele frequency (MAF) than genotyped SNPs. To test these1Queensland Institute of Medical Research, 300 Herston Rd, Herston, Queensl
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the proportion of variance explained by all SNPs in
GWAS for a quantitative trait.7 We showed that a substan-
tial proportion of genetic variation for human height was
associated with common SNPs. For complex diseases it
would be very useful to apply the same estimation proce-
dure to case-control GWAS data. However, there are three
issues that need to be overcome to be able to estimate
genetic variance for disease without bias and with compu-
tationally fast algorithms:
(1) Scale. For quantitative traits the scale of measure-
ment is the same as the scale on which heritability
is expressed. For disease traits, the phenotypes
(case-control status) are measured on the 0–1 scale,
but heritability is most interpretable on a scale of
liability.
(2) Ascertainment. In case-control studies the propor-
tion of cases is usually (much) larger than the prev-
alence in the population yet estimates of genetic
variation are most interpretable if they are not
biased by this ascertainment.
(3) Quality control (QC) of SNPs. QC is more of a
concern for case-control than quantitative GWAS.
For quantitative traits, experimental or genotyping
artifacts are unlikely to be correlated with the trait
value. However, case and control sets are often
collected independently so that experimental arti-
facts could make cases more similar to other cases
and controls more similar to other controls. These
artificial case-control differences could be parti-
tioned as ‘‘heritability’’ in methods that utilize
genome-wide similarity within and differences
between cases and controls.
In the present study, we overcome all three problems
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data show that genetic variation in liability to disease that
is in LD with common SNPs can be estimated from GWAS
data. The purpose of this paper is to present these methods
in detail. We demonstrate their application by using three
of the data sets from the Wellcome Trust Case Control
Consortium (WTCCC),13 Crohn disease, bipolar disorder,
and type I diabetes. We show that a substantial proportion
of variation in liability to these diseases is captured by
common SNPs.
Material and Methods
We first revisit the concept of using marker data to estimate real-
ized genetic relationships. Next we present the linear model
between binary phenotype and genetic effects (this is the same
model as used for continuous phenotypes) and use this model to
estimate genetic variance. We then demonstrate the derivation
of the classic relationship between additive genetic variance on
the disease and liability scales that allows interpretation of genetic
variance on the liability scale. For case-control studies, we adapt
this relationship to account for ascertainment that generates
a much higher proportion of cases in our analyzed sample
than in the population. The new theory is general and applicable
to any proportion of cases and controls in a case-control study. We
apply these methods first to simulated data in which we can vary
the disease prevalence and genetic variance explained by the SNPs.
We then apply these methods to real GWAS data by focusing on
stringent QC steps required to get meaningful results.Theory on Random Variables
Throughout subsequent derivations, we repeatedly make use of
a number of known results from statistical theory. For random
variables x and y, their variances and covariance are defined as
varðxÞ ¼ Eðx2Þ  EðxÞ2;
varðyÞ ¼ Eðy2Þ  EðyÞ2 (Equation 1)
and
covðx; yÞ ¼ EðxyÞ  EðxÞEðyÞ: (Equation 2)
The bivariate regression of y on x has regression coefficient
b ¼ covðx; yÞ=varðxÞ: (Equation 3)
If y follows a standard normal distribution with a truncation
point at t, with t > 0, so that the fraction of y that is larger than
t is K, then the mean value of y above the truncation point is
Eðy j y > tÞ ¼ i ¼ z=K; (Equation 4)
with z the height of the normal curve at point t.2,3 The mean for y
below the truncation point is
Eðy j y < tÞ ¼ iK=ð1 KÞ: (Equation 5)
The variance of y for values above and below the truncation
point are [1 i(i-t)] and [1 itK/(1-K)(tþ iK/(1 K)], respectively.2
It follows from the definition of the variance given above that
E

y2 j y > t ¼ ½1þ it (Equation 6)
and
E

y2 j y < t ¼ ½1 itK=ð1 KÞ: (Equation 7)The AmeriRealized Relationships between Distant Individuals
We showed previously that it is possible to estimate realized rela-
tionships between unrelated (in a conventional sense) individuals
from dense SNP data.7 A simple and logical method of estimating
realized additive genetic relationships (bAij) between individual i
and j is to use the products of genotype indicator coefficients
between two individuals scaled by the heterozygosity for all L
genotyped SNPs across the genome,7
bAij ¼ 1
L
XL
i¼1

xil  2pl

,

xjl  2pl

2plql
 ðisjÞ; (Equation 8)
where xil ¼ 0, 1, or 2 according to whether individual i has geno-
type bb, Bb, or BB at locus l (alleles are arbitrarily called b or B), p (q)
is allele frequency of B (b), and 2p is the mean of xl. As in Yang
et al.,7 we use the current population as the base (reference) pop-
ulation when estimating relatedness from SNP data so that
E(x) ¼ 2p in the current population. This implies that the average
pairwise relatedness is zero and that some pairs of individuals
are less related to each other than the average in the population,
leading to negative estimates. Relatedness in this definition is
not a probability (as in the classical definition of identity-by-
descent) but a correlation of additive genetic values.2,14 The esti-
mate of relatedness for an individual with him/herself (the
diagonal of the matrix) has a slightly different form to the off-
diagonals to minimize sampling variation,7
bAii ¼ 1þ 1
L
XL
i¼1

x2il 

1þ 2pl

xil þ 2p2l

2plql

:
Linear Mixed Model
In a model for analyzing disease, the observations (unaffected or
affected) can be expressed as a linear function of the sum of the
additive effects due to SNPs associated with causal variants and
residual effects. The linear model can be written as
y ¼ m1N þ uþ e (Equation 9)
where y is a vector of 0, 1 observations of disease status for N indi-
viduals, m is the overall mean, 1N is a vector of N ones, u is a vector
of random additive genetic effects from aggregate SNP informa-
tion, and e is a vector of residuals. The variance structure of pheno-
typic observations is written as V ¼ As2u þ Is2e , where A is the
realized relationship matrix estimated from SNP data, I is an iden-
tity matrix, s2u is polygenic additive genetic variance explained by
the SNPs, and s2e is error variance; these variances are on the
observed 0–1 scale. Therefore, the heritability on the observed
scale is h2o ¼ s2u=ðs2u þ s2e Þ, the ratio of total phenotypic variance
on that scale that is due to additive genetic effects. The variance
components are estimated via residual maximum likelihood
(REML) analysis.4,15,16
Liability Threshold Model
One can model the relationship between observations on the
observed risk scale and liabilities on the unobserved continuous
scale by using a probit transformation to generate the classical
liability thresholdmodel6 (Figure 1). Liability of disease is assumed
to be the sum of environmental and additive genetic components
from independent normal distributions. The advantages of
working on the scale of liability are that population parameters
such as variance components and heritability are independent
of prevalence and can therefore be compared across traits orcan Journal of Human Genetics 88, 294–305, March 11, 2011 295
Figure 1. The Liability Threshold Model for a Disease Preva-
lence of K
An underlying continuous random variable determines disease
status. If liability exceeds the threshold t, then individuals are
affected.populations and that statistical methods developed for quantita-
tive traits can be applied to the trait liability.2,6 The model can
be written as
l ¼ m1N þ g þ e (Equation 10)
where l is a vector of liability phenotypes that are distributed as
N(0, 1), g is a vector of random additive genetic effects on the
liability scale that are distributed N(0, s2g ), and other terms are
the same as in the linear model but on the liability scale. We
note that the mean of the distribution of liability is zero (m ¼ 0)
when there is no ascertainment. Therefore, because the total
phenotypic variance on the scale of liability is per definition equal
to 1 and the heritability is defined as the genetic variance as
a proportion of total variance, the heritability on the liability scale
is h2l ¼ s2g . In the liability threshold model, all affected individuals
have liability phenotypes exceeding a certain threshold value t
(Figure 1). The population prevalence is K ¼ E(y). Applying the
properties of truncated normal distributions2,17, Equations 4 and
5 give the mean liability
i ¼ Eðl j y ¼ 1Þ ¼ z=K for cases and (Equation 11)
i2 ¼ Eðl j y ¼ 0Þ ¼ z=ð1 KÞ ¼ iK=ð1 KÞ for controls;
(Equation 12)
and, Equations 6 and 7 then give the squared mean liability as
E

l2 j y ¼ 1 ¼ 1þ it for cases and (Equation 13)
E

l2 j y ¼ 0 ¼ 1þ i2t for controls: (Equation 14)
By using Equations 2, 11, and 12, we can derive the covariance
between y (unaffected/affected status) and l (liability) as296 The American Journal of Human Genetics 88, 294–305, March 1covðy; lÞ ¼ Eðy,lÞ  EðyÞEðlÞ ¼ K1iþ ð1 KÞ0i2 ¼ Ki ¼ z;where z is the height of the standard normal probability density
function at the truncation threshold t. The above derivations
describe the relationship between the phenotypes on the two
scales, but what we are interested in is the relationship between
genetic values on those scales. Following Dempster and Lerner,18
we determine the genetic value on the observed 0–1 risk scale
for an individual (u), defined in Equation 9, as
u ¼ c þ bg ¼ c þ zg; (Equation 15)
where c is a constant.
The linear regression coefficient that links the two scales is
derived from the regression of the phenotype on the observed
scale (y) on the additive genetic effect on the scale of liability (g),
and equals the covariance of y and g divided by the variance of g
(Equation 3),
b ¼ covðy; gÞ=s2g ¼ ½Eðy,gÞ  EðyÞEðgÞ=h2l ¼ Kih2l =h2l ¼ z:
(Equation 16)
Finally, the heritability on the observed scale is the genetic vari-
ance on the observed scale, s2u ¼ varðzgÞ ¼ z2s2g from Equation 15,
as a proportion of the total variance of 0–1 observations, which
is the Bernoulli distribution variance K(1  K) and can be
written as
h2o ¼ s2u=½Kð1 KÞ ¼ s2g
h
covðy; gÞ=s2g
i2
=½Kð1 KÞ
¼ s2g b2=½Kð1 KÞ ¼ h2l z2=½Kð1 KÞ:
This can be rearranged to transform the heritability on the
observed scale to that on the liability scale as
h2l ¼ h2oKð1 KÞ=z2: (Equation 17)
This linear transformation was derived by Alan Robertson in the
Appendix of Dempster and Lerner.18 When applied to estimates of
genetic variation on the observed scale derived from family data,
this transformation can give biased estimates on the liability scale
because the genetic variation estimable from close relatives
contains both additive and nonadditive variance.18,19 However,
when the genetic variance is estimated from distant relatives,
the nonadditive genetic component of the variance is small
relative to the additive component, and so the Robertson transfor-
mation provides a good approximation. Because we are using
genetic relationships between ‘‘unrelated’’ individuals, the Robert-
son approximation is valid in samples without ascertainment.
However, in order to obtain a relationship between the estimates
of heritability on the two scales, we need to account for the
inflated proportion of cases in case-control designs.
Ascertainment-Corrected Transformation to the
Estimated Variance in a Case-Control Study
to Estimate h2l
We consider the same liability model when the proportions of
cases and controls are not a random sample from the population
(Figure 2). The mean and variance for case and control disease
status (ycc), disease liability (lcc), and genetic liability (gcc) following
quantitative genetic theory2 are
E

ycc
 ¼ P; which is the proportion of cases in the sample
ðusually 1=2Þ;1, 2011
Figure 2. The Distribution of Liability When Cases Are Over-
sampled as in a Case-Control Studyvar

ycc
 ¼ Pð1 PÞ; which is the phenotypic variance on the
observed scale in the case-control sample; and
EðlccÞ ¼ Piþ ð1 PÞi2 ¼ il; where we define l ¼ ðP  KÞ=ð1 KÞ:
Using Equations 1, 13, and 14 then gives,
varðlccÞ ¼ s2lcc ¼ E

l2cc
 EðlccÞ2¼ Pð1þ itÞ þ ð1 PÞð1þ i2tÞ  i2l2
¼ 1þ Pit  ð1 PÞtiK=ð1 KÞ  i2l2 ¼ 1þ ilðt  ilÞ ¼ 1þ q;
(Equation 18)
where q ¼ ilðt  ilÞ, that is, the variance of liability is greater than
1 in a case-control study because individuals from the tails of the
distribution of liability have been selected. Because cases (and
controls) are ascertained on the observed phenotypic scale, the
mean of genetic liability depends on the mean liability phenotype
of the cases and the heritability of liability,
EðgccÞ ¼ h2l EðlccÞ ¼ h2l ½Piþ ð1 PÞi2 ¼ h2l il:
By using Equations 1, 13, 14, and 18 with the heritability of
liability, we can derive the variance for genetic liability as
varðgccÞ ¼ s2gcc ¼ E

g2cc
 EðgccÞ2¼ h2l El2cc h2l EðlccÞ2
¼ h2l ½Pð1þ itÞ þ ð1 PÞð1þ i2tÞ  h4l i2l2 ¼ h2l

1þ h2l q

:
The expression for s2gcc was previously derived in the context
of estimation of the accuracy of predicting the genetic risk of
disease from case-control studies.20 As for the situation of no
ascertainment, we are interested in the regression of phenotype
on the observed risk scale on genetic liability in the case-control
study,The Ameribcc ¼ cov

ycc; gcc

varðgccÞ ¼

E

ycc,gcc
 EyccEðgccÞvarðgccÞ    Pð1 PÞ s2¼ h2l iP  h2l ilP s2gcc ¼ Ph2l ið1 lÞ s2gcc ¼ z Kð1 KÞ gs2gcc :
(Equation 19)
The term Pð1PÞKð1KÞ
s2g
s2gcc
quantifies the change of the regression coef-
ficient due to ascertainment in a regression of phenotype on the
observed risk scale onto genetic factors on the scale of liability.
In the absence of ascertainment (P ¼ K), this term is 1.
According to Equation 15, the genetic value on the observed
scale (ucc) for an individual in a case-control study is
ucc ¼ c þ bccgcc ¼ c þ z Pð1 PÞ
Kð1 KÞ
s2g
s2gcc
gcc;
and
s2ucc ¼ b2ccs2gcc ¼
"
z
Pð1 PÞ
Kð1 KÞ
s2g
s2gcc
#2
s2gcc ¼

z
Pð1 PÞ
Kð1 KÞ
2 s2g
s2gcc
s2g :
(Equation 20)
We note that ucc is a least-squares estimate of the genetic value
on the observed scale. When residuals are normally distributed,
the least-square estimate is the same as the (residual) maximum-
likelihood estimate. However, normality of liability is violated in
a case-control study. The previous section describes the theoretical
relationships between parameters on different scales in the pres-
ence of ascertainment. In practice, we do not observe parameters
directly but estimate them. We now consider the relationship
between the parameters and their estimates when maximum like-
lihood is used to estimate the variance components.
The estimated genetic variance on the observed scale from
REML analysis (Equation 9) is based on 0–1 observations and the
covariance structure among samples. Without ascertainment,
the mean of estimated genetic values on the observed scale can
be derived from Equations 11, 12, 15, and 16 as Eðbujy ¼ 1Þ ¼
zis2g for cases and Eðbujy ¼ 0Þ ¼ zi2s2g for controls. When samples
are ascertained, the mean of the estimated genetic values is
E
bucc j ycc ¼ 1 ¼ P
K
ð1 PÞ
ð1 KÞ
ð1 PÞ
ð1 KÞE
bu j y ¼ 1 for cases
(Equation 21)
and
E
bucc j ycc ¼ 0 ¼ P
K
ð1 PÞ
ð1 KÞ
P
K
E
bu j y ¼ 0 for controls;
where the term PK
ð1PÞ
ð1KÞ is due to the increased proportion of cases
and the decreased proportion of controls, that is, in an ascertained
case-control study, themean genetic liability for cases can be trans-
formed to that on the observed scale by bcci
s2gcc ¼ PK ð1PÞð1KÞzis2g and
bcci

2s
2
gcc
¼ PK ð1PÞð1KÞzi2s2g from Equations 11, 12, 15, and 19 and
i ¼ i ð1PÞð1KÞ and i2 ¼ i2 PK, which is derived as follows. According to
Equation 17, h2l ¼ h2oKð1 KÞ=z2 ¼ bh2occ Pð1 PÞ=bz2cc, where bh2occ is
estimated heritability on the liability scale in an ascertained case-
control study and bz2cc is a squared regression coefficient that trans-
forms the estimate of genetic factors on the observed risk scale to
that on the liability scale. This expression can be written as
s2u
Kð1KÞ
1
z
Kð1KÞ
z ¼
bs2ucc
Pð1PÞ
1bzcc Pð1PÞbzcc . But from Equations 17, 19, and 20,
the terms
s2u
Kð1KÞ
1
z on the left-hand side and
bs2ucc
Pð1PÞ
1bzcc on the
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right-hand side are the same. Therefore, Kð1KÞz ¼ Pð1PÞbzcc results in the
expressions i ¼ bzccP ¼ i ð1PÞð1KÞ and i2 ¼  bzccð1PÞ ¼ i2 PK that were given
above. The REML estimate of the genetic variance (bs2u or bs2ucc ) is
the covariance between observations and the unbiased estimate
of the genetic values (bu or bucc) with a normality assumption, that
is, the regression of phenotype on predictor has a slope of 1,
covðy; buÞ=bs2u ¼ 1 or covðycc; buccÞ=bs2ucc ¼ 1. Therefore,
bs2u ¼ covy; bu ¼ Ey,bu EðyÞEbu ¼ Ey,bu ¼ Ebu j y ¼ 1,K
(Equation 22)
and
bs2ucc ¼ covycc; bucc ¼ Eycc,bucc EyccEbucc ¼ Eycc,bucc
¼ Ebucc j ycc ¼ 1,P:
from Equations 21 and 22 and bs2u ¼ z2bs2g from Equation 15
give us
bs2ucc ¼ PK ð1 PÞð1 KÞ
2bs2u ¼ z PK ð1 PÞð1 KÞ
2bs2g :
Wenote that in an ascertained case-control study, the REML esti-
mate is larger than the least-square estimator (Equation 20) by
a factor s2gcc=s
2
g , i.e.,
bs2ucc ¼ ðs2gcc=s2g Þs2ucc . This difference is due to
the normality assumption in REML. Therefore,
h2l ¼ s2g ¼ bs2ucc1z Kð1 KÞPð1 PÞ
2
¼ bh2occKð1 KÞz2 Kð1 KÞPð1 PÞ :
(Equation 23)
In the absence of ascertainment (P ¼ K), this equation reduces
to Equation 17, hence adjusting for ascertainment when variance
components are estimated by maximum likelihood leads
to a generalization of the classical Robertson transformation.
Equation 23 shows the transformation that needs to be applied
to the SNP-attributable variance estimated from Equation 9
to provide an estimate of the liability variance in the total
population explained by the SNPs. The sampling variance of
estimated heritability on the liability scale transformed from
that on the observed scale can be derived with a Taylor series
expansion,
var

h2l
  " dh2l 
d
	
h2occ

#2var	h2occ
 ¼ Kð1 KÞz2 Kð1 KÞPð1 PÞ
2
var
	
h2occ


:
(Equation 24)
With extreme ascertainment, for example, K < 0.01 and P ¼ 0.5,
a high heritability on the liability scale transforms to a greater
genetic than phenotypic variance on the observed scale according
to Equation 23. This is not a problem for the estimation of the
genetic variance. When using REML or ML for estimation, it is
possible to maximize the likelihood for the genetic variance on
the observed scale even if it is larger than the observed phenotypic
variance on that scale. Therefore, we can correctly estimate the
heritability on the liability scale even with extreme K and high
heritability on the liability scale.
In summary, in practice we can estimate the variance ex-
plained on the 0–1 risk scale in a case-control design by using
a LMM and transform both the estimate and its standard error
to the scale of liability while adjusting simultaneously for ascer-
tainment.298 The American Journal of Human Genetics 88, 294–305, March 1Simulated Data
To test the estimation of genetic variance on the liability scale
from ascertained case-control data, we performed a simulation
study. For each simulation replicate we generated 5000 cases and
5000 controls. To achieve a low level of relatedness, we simulated
individuals in independent batches of 100 with genetic values (g)
drawn from a multivariate normal distribution given a 100 3
100 covariance matrix (the mvrnorm function in the R package
was used21). Elements of the covariance matrix were 0.05 s2g for
off-diagonals and s2g for diagonals. Environmental effects were
sampled from a normal distributionwith amean of zero and a vari-
ance of s2e , with s
2
e chosen such that the desired heritability of
liability was obtained. As in equation (10), liability, l, for each indi-
vidual consists of genetic effects, g, and residuals, e, on the liability
scale; that is, l¼ g þ e. Disease status for each individual was deter-
mined by comparing l with the threshold of liability determined
by the population prevalence. For example, for K ¼ 0.1, individ-
uals were assigned to be a case if l > 1.282sl. From each batch,
all cases and an equal number of randomly selected controls
contributed to the case-control sample. We continued simulating
batches of individuals until the desired sample size of 5000 cases
and 5000 controls was achieved. The pairwise relationships
between individuals in the case-control sample were 0.05 if they
both came from the same set and zero otherwise.
For the analysis of the simulated data, we used the LMM Equa-
tion 9 with the transformation that was derived in Equation 23.
Simulations were performed for K¼0.001, 0.01, 0.10, 0.20, and
0.5, and the case-control samples were generated either without
ascertainment (P ¼ K) or with ascertainment (P > K), where each
set of 100 individuals contributed approximately the same
number of cases and controls. A range of values of heritability
on the liability scale, h2l , were tested. One hundred simulation
replicates were conducted for each scenario.
Real Data
We applied our estimationmethod toWTCCCGWAS data,13 geno-
typed on the Affymetrix 5.0 platform. QC is important with real
data because artificial allele frequency differences between cases
and controls will generate a spurious ‘‘heritability.’’ As a test of the
robustness of the method, we first used the two independent
control samples and pretended they formed a case-control study.
One of the two control groups was treated as a case group, and the
other was treated as a control group in the analysis. Subsequently,
we estimated genetic variance explained by all SNPs by analyzing
case samples for Crohndisease, bipolar disorder, and type I diabetes
alongwith the combined data set of the two control samples.We fit
the first 20 principal components as covariates in the LMM (Equa-
tion 9) to correct for possible population structure.22
For each data set, a standard QC procedure was performed. SNPs
with MAFs <0.01 and missing rates >0.05 were excluded as were
individuals with missing rates >0.01. Because small errors for
each SNP can be accumulated to give incorrect estimates for
genetic variance, additional QC steps were extremely stringent.
We excluded SNPs whose p values were<0.05 for the Hardy-Wein-
berg (H-W) equilibrium test and for missingness-difference
between cases and controls. We also applied a two-locus test based
on the difference in the test statistic of association between single
SNPs and pairs of adjacent SNPs.23 Sex chromosomes were
excluded from the analysis. To keep individuals who were only
distantly related, both individuals from a pair with an estimated
relationship >0.05 were excluded; to benchmark this threshold,
relationships approximately closer than second cousins were1, 2011
Table 1. Simulation Results: Estimated Heritability on the Liability Scale and Empirical Standard Error over Replicates
Prevalence of Disease
in the Population (K)
Heritability of Liability
0.1 0.3 0.5 0.7 0.9
K ¼ 0.5 0.09 (0.006) 0.28 (0.010) 0.51 (0.013) 0.70 (0.016) 0.90 (0.016)
K ¼ 0.2 0.10 (0.007) 0.31 (0.009) 0.49 (0.011) 0.71 (0.012) 0.91 (0.013)
K ¼ 0.1 0.11 (0.007) 0.30 (0.009) 0.49 (0.009) 0.71 (0.012) 0.89 (0.012)
K ¼ 0.01 0.11 (0.009) 0.30 (0.011) 0.49 (0.012) 0.70 (0.013) 0.90 (0.012)
K ¼ 0.001 0.17 (0.020) 0.31 (0.020) 0.56 (0.021) 0.75 (0.021) 0.94 (0.022)
In all examples the proportion of cases in the case-control sample was p¼ 0.5. Sample size was 10,000 (5000 cases, 5000 controls) for all situations. The number of
replicates was 100.removed. After the stringent QC process, the number of samples
and SNPs used for estimating genetic variance were 2599 individ-
uals (1395 cases and 1204 controls) and 309,040 SNPs for the
control-control contrast study, 3833 individuals (1504 cases and
2329 controls) and 322,142 SNPs for Crohn disease, 3880 individ-
uals (1433 cases and 2447 controls) and 321,605 SNPs for bipolar
disorder, and 4063 individuals (1640 cases and 2423 controls) and
318,044 SNPs for type I diabetes.
To investigate the robustness of our variance estimates, we also
considered more stringent threshold values for SNP missing rates
(fewer than 20, 7, or 4 genotypes per SNP) and MAF (>0.05). To
benchmark these thresholds, we note that a SNP missing rate of
0.05 is approximately equal to a maximum of 200 missing geno-
types per SNP.
Each QC step was designed to remove potential artifacts from
contributing to the estimate of genetic variance. However, each
step also reduces the number of SNPs used for estimation of the
genetic variance. As the number of SNPs decreases, the LD
between genotyped and causal variants also decreases, and so esti-
mates of genetic variance are expected to decrease. To determine
whether any observed reduction in estimated genetic variance
was a consequence of the reduced number of SNPs rather than
the QC criteria per se, we adjusted the estimate of variance to
take account of imperfect LD between the genotyped SNPs. That
is, we adjusted the estimate because pairwise relatedness is esti-
mated with error. We described previously how this adjustment
was made.7 Subsequent to the adjustment for using a finite
number of SNPs, we used the transformation in Equation 23 to
obtain an estimate on the liability scale that takes account of ascer-
tainment of cases in a case-control sample. In the transformation,
we assumed a population prevalence of 0.1%, 0.5%, and 0.5% for
Crohn disease, bipolar disorder, and type I diabetes, respec-
tively.13,24–26 Hence, our procedure was as follows: (1) REML anal-
ysis of 0–1 data using relatedness estimated from SNP data,16 (2)
adjustment for the number of SNP used to construct relationships,
and (3) adjustment for scale and ascertainment.Results
Simulations
WeusedREML to estimateheritability on the observed scale,
and we transformed estimates to the liability scale with the
ascertainment correction from Equation 23. When simu-
lated data with K ¼ P ¼ 0.5 (no ascertainment) were used,
the estimated heritabilities on the liability scale were unbi-The Ameriased and close to the true values, as expected (Table 1).
When ascertained case-control studies were used, the esti-
mates were largely unbiased although a slight overestima-
tionwasobserved for anextremevalueofK¼0.001 (Table1).Estimated Genetic Variance from the WTCCC Data
after Stringent QC
In preliminary analyses, we recognized the importance of
imposing stringent QC on H-W equilibrium, on differen-
tial missingness between cases and controls, and on
a two-locus QC test (see Figures S1–S3, available online).
Genotyping conducted on other platforms might not
require this level of stringency. We conducted a range of
additional tests and checks to ensure the validity of our
results (see Discussion and Supplemental Data).
Control-Control Contrast Study
Estimates for genetic variance between the two control
groups were not significantly different from zero, as ex-
pected (Table 2). The estimate and its likelihood ratio grad-
ually decreased when the threshold for the SNP missing
rate decreased. When SNPs with an MAF > 0.01 and
missing <4 genotypes/SNP were used, the estimate was
0.06 (SE ¼ 0.11). When SNPs with an MAF > 0.05 were
used, the decreasing patterns of the estimates and their
likelihood ratios were very similar to those of SNPs with
an MAF > 0.01. The estimated values observed when
SNPs with an MAF > 0.05 were used were slightly higher
than those with an MAF > 0.01 although the difference
was small. These results suggest that our QC procedure
was stringent enough to allow robust estimates of genetic
variation, that is, the likelihood ratio was already not
significant for a SNP genotype missingness of up to 200.
Crohn Disease
We investigated the impact of SNPmissingness on the esti-
mates of variance explained by SNPs for Crohn disease.
While the threshold for missingness becomes more strin-
gent, the number of SNPs reduces from ~322,000 to
~196,000 when MAF > 0.01 (Table 3). While this happens,
the raw proportion of variance estimate drops from 0.56 to
0.50. Part of this decline is due to the reduced number of
SNPs used rather than artifacts of genotype missingness.
After we adjust for the number of SNPs, the proportion ofcan Journal of Human Genetics 88, 294–305, March 11, 2011 299
Table 2. Estimated Genetic Variance in the Observed Scale
Explained by All SNPs for Two Control Samples in the WTCCC Data
Thresholda No. SNPb Estimatec (SE) LRd p valuee
MAF > 0.01
200 309,040 0.17 (0.11) 2.29 0.07
20 297,198 0.13 (0.11) 1.31 0.13
7 266,534 0.08 (0.11) 0.59 0.22
4 226,165 0.06 (0.11) 0.29 0.30
MAF > 0.05
200 278,564 0.19 (0.11) 3.42 0.03
20 267,043 0.16 (0.10) 2.33 0.06
7 239,614 0.12 (0.10) 1.33 0.12
4 203,698 0.09 (0.10) 0.92 0.17
a Excluding SNPs with more than the listed number of missing genotypes. Two
hundred missing genotypes are approximately equal to a missingness rate of
5% (depending on sample size).
b After filtering on the basis of SNP missing rate.
c Estimate of genetic variance proportional to the total phenotypic variance on
the observed scale.
d Likelihood-ratio test statistic.
e p values were calculated assuming that the LR is distributed as a 50:50
mixture of zero and c21 under the null hypothesis.variance estimate drops from 0.64 to 0.61 but reaches
a plateau at that value (Table 3, Adjusted column). Therefore
we conclude that there is no need to make the missing
threshold more stringent than 20. On the liability scale, the
heritability estimate (i.e., the variance in liability explained
by the SNPs) is 0.22 (SE ¼ 0.04), which is much higher than
that explained by genome-wide significant SNPs.27 Similar
results are obtained if the SNPs with MAF >0.05 are used
(Table 3). This indicates that common SNPs (MAF > 0.05)
are in substantial LD with casual variants for Crohn disease.Table 3. Estimated Genetic Variance on the Observed and Liability Sc
Thresholda No. SNPb Estimatec (SE)
MAF > 0.01
200 322,142 0.56 (0.07)
20 294,850 0.53 (0.07)
7 248,791 0.52 (0.07)
4 195,977 0.50 (0.07)
MAF > 0.05
200 293,269 0.56 (0.07)
20 266,843 0.53 (0.07)
7 225,043 0.52 (0.07)
4 177,615 0.50 (0.07)
a Excluding SNPs with more than the listed number of missing genotypes.
b After filtering on the basis of SNP missing rate.
c Estimate of genetic variance proportional to the total phenotypic variance on t
d Estimate adjusted for reduced number of SNPs.
e Transformed genetic variance proportional to the total phenotypic variance on t
the heritability on the liability scale explained by the SNPs.
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For bipolar disorder, we found that we needed a slightly
more stringent threshold for SNP missingness than for
Crohn disease. When we excluded SNPs with an MAF <
0.01 and missing rate >200, the heritability estimate on
the liability scale was 0.4 (Table 4). The estimates gradually
decreased and became stable after we excluded SNPs
with more than seven missing genotypes. The estimated
value was 0.38 (SE ¼ 0.04). When we used SNPs with an
MAF > 0.05, the decreasing pattern of the estimate and
its likelihood was similar to that with an MAF > 0.01,
and the values were slightly lower than those with an
MAF > 0.01. When we used SNPs with missingness of <7
or <4 genotypes, we obtained a stable estimate of ~0.37
(SE~0.04) (Table 4).
Type I Diabetes
When we used SNPs with an MAF > 0.01 and missingness
of <200 genotypes, the estimates on the liability adjusted
for reduced number of SNPs was 0.32 (SE ¼ 0.04). After
excluding SNPs with a missingness of >7 genotypes, esti-
mates and likelihood ratio showed little change (Table 5).
The estimate was 0.30 (SE ¼ 0.04) for a missingness <7
genotypes and 0.31 (SE ¼ 0.04) for a missingness of <4
genotypes. When SNPs with an MAF > 0.05 were used,
estimated values were slightly lower compared to those
with an MAF > 0.01. The estimate was 0.28 (SE ¼ 0.04)
for a missingness of <7 genotypes, and 0.29 (SE ¼ 0.04)
for <4 missing genotypes (Table 5). For type I diabetes,
some SNPs on chromosome 6 had extremely significant
associations, for example, WTCCC13 reported a p value
of 5.47e-134 for rs9272346 in the region of the major
histocompatibility complex (MHC). We performed an
analysis without chromosome 6 or with chromosome 6
only when we used SNPs with an MAF > 0.01 (Table 6).
We observed that the estimates substantially decreasedale Explained by All SNPs for Crohn Disease in WTCCC Data
LR Adjustedd (SE) Transformede (SE)
63.16 0.64 (0.08) 0.24 (0.03)
57.48 0.61 (0.08) 0.22 (0.03)
57.30 0.61 (0.08) 0.22 (0.03)
54.94 0.60 (0.08) 0.22 (0.03)
69.00 0.63 (0.08) 0.23 (0.03)
63.27 0.60 (0.08) 0.22 (0.03)
63.94 0.60 (0.08) 0.22 (0.03)
62.14 0.60 (0.08) 0.22 (0.03)
he observed scale.
he liability scale under the assumption that the population prevalence is 0.1%,
1, 2011
Table 4. Estimated Genetic Variance on the Observed and Liability Scale Explained by All SNPs for Bipolar Disorder in WTCCC Data
Thresholda No. SNPb Estimatec (SE) LR Adjustedd (SE) Transformede (SE)
MAF > 0.01
200 321605 0.71 (0.07) 107.76 0.81 (0.08) 0.41 (0.04)
20 291724 0.68 (0.07) 100.48 0.78 (0.08) 0.40 (0.04)
7 245127 0.65 (0.07) 94.69 0.76 (0.08) 0.38 (0.04)
4 187597 0.62 (0.07) 92.21 0.76 (0.08) 0.38 (0.04)
MAF > 0.05
200 292969 0.68 (0.07) 110.45 0.77 (0.08) 0.39 (0.04)
20 264151 0.65 (0.07) 103.46 0.75 (0.08) 0.38 (0.04)
7 221947 0.62 (0.07) 97.64 0.72 (0.08) 0.37 (0.04)
4 170143 0.60 (0.06) 95.47 0.73 (0.08) 0.37 (0.04)
a Excluding SNPs with more than the listed number of missing genotypes.
b After filtering on the basis of SNP missing rate.
c Estimate of genetic variance proportional to the total phenotypic variance on the observed scale.
d Estimate adjusted for reduced number of SNPs.
e Transformed genetic variance proportional to the total phenotypic variance on the liability scale under the assumption that the population prevalence is 0.5%.when we excluded chromosome 6 from the analysis; that
is, it decreased to 0.13 (SE ¼ 0.04). On the other hand,
the estimate based on SNPs on chromosome 6 was rela-
tively high, that is, 0.19 (SE ¼ 0.01) (Table 6). Hence,
although the known risk locus on chromosome 6 explains
a substantial proportion of variation in liability to type I
diabetes, common SNPs on other chromosomes explain
a substantial additional proportion of variation.
Discussion
In this study, we have provided a computationally fast
method of estimating the proportion of variation in disease
liability that is captured in GWAS by considering all SNPsTable 5. Estimated Genetic Variance on the Observed and Liability Sc
Thresholda No. SNPb Estimatec (SE)
MAF > 0.01
200 318,044 0.57 (0.07)
20 289,463 0.56 (0.07)
7 238,805 0.52 (0.07)
4 178,892 0.51 (0.07)
MAF > 0.05
200 289,693 0.54 (0.07)
20 262,091 0.53 (0.07)
7 216,136 0.49 (0.06)
4 162,162 0.48 (0.06)
a Excluding SNPs with more than the listed number of missing genotypes.
b After filtering on the basis of SNP missing rate.
c Estimate of genetic variance proportional to the total phenotypic variance on t
d Estimate adjusted for reduced number of SNPs.
e Transformed genetic variance proportional to the total phenotypic variance on t
The Amerisimultaneously. Compared to previous analyses on quanti-
tative traits, we needed three improvements: (1) a suitable
transformation from the 0–1 risk scale to an underlying
scale of liability, (2) a proper adjustment to take account
of the fact that case-control proportions are not the
same as the proportion of cases and controls in the popula-
tion, and (3) a calibration of SNP and sample QC to
avoid spurious case-control differences in relatedness. We
demonstrated by simulation that the LMM implementa-
tion gives unbiased estimates and applied the method to
WTCCC data. We showed that a substantial proportion of
disease liability is tagged by common SNPs for Crohn
disease, bipolar disorder, and type 1 diabetes. To implement
these methods, we have created a user-friendly softwareale Explained by All SNPs for Type I Diabetes in WTCCC Data
LR Adjustedd (SE) Transformede (SE)
70.36 0.65 (0.08) 0.32 (0.04)
70.32 0.65 (0.08) 0.32 (0.04)
61.51 0.61 (0.08) 0.30 (0.04)
64.74 0.64 (0.08) 0.31 (0.04)
70.48 0.61 (0.08) 0.30 (0.04)
70.49 0.61 (0.08) 0.30 (0.04)
61.81 0.57 (0.08) 0.28 (0.04)
63.54 0.58 (0.08) 0.29 (0.04)
he observed scale.
he liability scale under the assumption that the population prevalence is 0.5%.
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Table 6. Estimated Genetic Variance on the Observed and Liability Scale Explained by All SNPs for Type I Diabetes from anAnalysis without
Chromosome 6 or of Chromosome 6 Only
Thresholda No. SNPb Estimatec (SE) LR Adjustedd (SE) Transformede (SE)
Analysis without chromosome 6
200 297,028 0.23 (0.07) 11.98 0.26 (0.08) 0.13 (0.04)
20 270,332 0.22 (0.07) 10.66 0.25 (0.08) 0.12 (0.04)
7 223,039 0.20 (0.07) 9.08 0.23 (0.08) 0.12 (0.04)
4 167,099 0.20 (0.06) 10.17 0.26 (0.08) 0.13 (0.04)
Analysis of chromosome 6 only
200 21,016 0.33 (0.02) 268.55 0.37 (0.03) 0.18 (0.01)
20 19,131 0.33 (0.02) 278.09 0.37 (0.03) 0.18 (0.01)
7 15,766 0.32 (0.02) 255.65 0.36 (0.03) 0.18 (0.01)
4 11,793 0.31 (0.02) 264.63 0.38 (0.03) 0.19 (0.01)
a Excluding SNPs with more than the listed number of missing genotypes.
b After filtering on the basis of SNP missing rate.
c Estimate of genetic variance proportional to the total phenotypic variance on the observed scale.
d Estimate adjusted for reduced number of SNPs.
e Transformed genetic variance proportional to the total phenotypic variance on the liability scale assuming that the population prevalence is 0.5%. SNPs with an
MAF > 0.01 were used.tool that is called Genome-wide Complex Trait Analysis
(GCTA) and that is available from the our website.28
The estimation of the variance explained by all SNPs is
important because it tells us how much genetic variation
is in linkage disequilibrium with SNPs on commercial
arrays. It has direct impact on further experimental design,
for example on the decision whether to invest in ever
larger GWAS samples or whether to sequence a smaller
number of samples. The difference between the proportion
of disease liability variation accounted for by robustly asso-
ciated SNPs, as in standard GWAS analysis, and our
method is that we focus on estimation rather than on strin-
gent hypothesis testing. Causal variants that are in LDwith
common SNPs but have small effect sizes are not detected
by GWAS but do contribute to genetic variation in our
method. Our method cannot differentiate between
whether the variance detected represents LD with causal
variants that are common or rare. However, it is very
unlikely that the detected variation represents only rare
variants, and the results provide further evidence that
common variants contribute to the genetic architecture
of complex genetic disease. Our results suggest that ever
larger GWAS samples will continue to identify robustly
associated variants that could reflect both common and
rare causal variants. The robustly associated variants will
continue to provide information about the underlying
biology, and construction of genomic profiles from
genome-wide SNPs can be useful in genetic-risk predic-
tion.29 With increasing sample size, the proportion of vari-
ance explained in validation samples by using genomic
profiles developed from discovery samples will approach
the proportion of variance that we have estimated to be
tagged by all of the SNPs.302 The American Journal of Human Genetics 88, 294–305, March 1In order to estimate the proportion of variance explained
by SNPs on the liability scale, we needed to derive a trans-
formation from the variance estimated on the observed
scale, accounting for the ascertainment typical of case-
control studies. Without ascertainment, the range of heri-
tability on the observed scale is smaller compared to
that on the liability scale (see Figure 2 of Dempster and
Lerner18). However, because there is a much higher propor-
tion of cases in case-control studies than in the general
population, the range on the observed scale is larger than
that on the liability scale. For example, when K ¼ 0.01
and P ¼ 0.5, proportions of variance estimated on the
observed scale of 0.18, 0.54, and 0.91 correspond to a heri-
tability on the liability scale of 0.1, 0.3, and 0.5. Therefore,
a large change of heritability on the observed scale
becomes relatively small on the liability scale, particularly
for an extreme ascertainment. This is why the standard
errors for values on the liability scale were small relative
to those on the observed scale when the WTCCC data
were used.
We used a linear model for estimation of the variance
attributable to SNPs (Equation 9). Nonlinear models
might be considered a reasonable and appropriate alterna-
tive. However, generalized LMMs (GLMMs) that use
maximum likelihood for estimation and approximations
to avoid numerical integration30 and that have been
widely used for binary traits have a problem of serious
bias induced by the approximations.31 In addition, these
methods do not take account of ascertainment typical of
case-control studies. We explored GLMM by using Markov
Chain Monte Carlo sampling methods and observed that
although it gives unbiased estimates in the absence of
ascertainment, estimates were biased when samples were1, 2011
ascertained (results not shown). In addition to the problem
of bias, GLMMmethods are computationally much slower
than LMMs.
Stringent QC is important for the analyses we have per-
formed because artificial allele frequency differences
between cases and controls will result in apparent genetic
variance. We explicitly checked data quality with various
tests, aiming to avoid spurious results. We applied a very
stringent threshold (p value < 0.05) for the H-W equilib-
rium test because more SNPs showed weak departures
from equilibrium than expected by chance (Figure S1).
There were SNPs whose missing rate was significantly
different between cases and controls. These SNPs could
be problematic because of artifact effects and would influ-
ence estimation of genetic variance. We excluded SNPs
with p value < 0.05 for differential missingness. After
excluding these SNPs, we assessed data quality by test
statistics from a comparison of single and pairwise SNP
analyses by using a two-locus QC test23 (Figure S2).
Although a large number of problematic SNPs and erro-
neous signals had gone after filtering out SNPs whose
differential missingness was significant, there were still
a number of potentially problematic SNPs (e.g., 963 data
points deviating from expectation in Figure S2). We subse-
quently applied more stringent QC allowing only 20 or
only four missing genotypes across all samples, i.e., a SNP
missingness rate of <20/N (¼ ~0.005) and 4/N (¼ ~0.001),
and we showed how the erroneous signals changed
(Figure S3), where N is the total sample size. Therefore, it
is likely that only high-quality SNPs are retained for pheno-
type-genotype analysis. We visually checked the distribu-
tions of diagonal and off-diagonal elements from the
estimated relationship matrices. We generated histograms
of the distributions of the diagonal and off-diagonal
(Equation 8) elements of the estimated realized additive
genetic relationship matrix (Figures S4–S9). The distribu-
tions of the control-control and case-case off-diagonals are
centered slightly higher than the distribution of the case-
control off-diagonals. The means and standard deviations
are presented in Tables S1 and S2. Additionally, we per-
formed a number of analyses to make sure that there was
no estimation bias due to artifacts. Heterogeneity for two
independent sets of case-control studies was tested (Table
S3). Haseman-Elston regression for the control-control
contrast study was performed (Table S4). The original
WTCCC study13 reported that ‘‘selected samples were
normalized to 50 ng ml21 and rearrayed robotically into
96-well plates so that each plate was composed of 94
samples representing at least two different collections at
a ratio of 1:1. For each collection, the selected samples
were balanced first for sex and then geographical region.’’
Given this statement, age (at which the participants
entered a study) might be more vulnerable to be associated
with systematic artifact bias due to batch or plate effects
than sex or geographical region. After removing problem-
atic SNPs, we hypothesized that individual relationships
within an age group should not be more related than thoseThe Ameriacross the rest of age groups. This was tested by Haseman-
Elston regression in which a case-control study where the
individuals from one age group were treated as cases
and the other individuals were treated as controls. (Tables
S5–S8). A case-case contrast study was carried out to check
whether genotypes from cases with different diseases
were too similar to each other (Table S9). In bivariate
analyses, we showed that the genetic correlations between
the three diseases were not significantly different from
zero (Table S10). From the test results, we concluded
that there were no apparent artifacts that were confounded
with genetic effects. However, ultimate confirmation
will come from replication analyses in other independent
data sets.
Our estimate of the proportion of variation in liability
that is tagged by all SNPs relies on knowledge of the
population prevalence (K), just as it does when one esti-
mates total heritability of liability from pedigree or twin
analyses by using binary traits. What is the effect of mis-
specifying this population parameter? We derived the
ratio of bias in the estimate of the total variance of
liability explained up to a two-fold misspecification of
disease prevalence, that is, bK ¼ 0.5K, 0.75K, 1.5K, or 2K
(Table S11). For a misspecification of bK ¼ 0.75K or 1.5K,
the ratio of bias was small, at 0.91–1.14, for all values of
K; a value of 1.0 indicates no bias. For bK ¼ 0.5K or 2K,
the ratio of bias increased, and the range for the value
K ¼ 0.1 was largest (0.81~1.24). Therefore, misspecifying
the population prevalence by a factor of two results in an
upward or downward bias of the estimate of the proportion
of variance in liability explained by all SNPs of approxi-
mately 20%.
In conclusion, we have developed the methodology
needed to estimate the proportion of variance explained
on the liability scale in the population by sets of SNPs
on the basis of observations in ascertained samples of
cases and controls. We have tested our methodology by
simulation and by application to real GWAS data for
three diseases and have implemented our methodology
into freely available software.28 Stringent QC of GWAS
data is necessary to prevent inflated estimates of herita-
bility attributable to artifactual differences between
case and control genotypes. Using genotypes from Affy-
metrix 5.0, we estimate that for Crohn disease, bipolar
disorder, and type I diabetes, genotyped SNPs tag
between a quarter and one half of the heritability esti-
mated from family studies. Our estimates provide an
upper limit on the variance that can be explained in
genomic profiling as sample sizes increase when the
same genotyping platform is used. Genotyping platforms
with more SNPs are expected to tag more of the genetic
variance. We show that a good proportion of the herita-
bility is not missing. The variance explained by the SNPs
is likely to tag both common and rare causal variants. We
anticipate that a proportion of the heritability will always
remain missing, reflecting rare causal variants of small
effect.can Journal of Human Genetics 88, 294–305, March 11, 2011 303
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